{"altmetric_id":11765423,"counts":{"readers":{"mendeley":6,"citeulike":0,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["apo"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa62c3cf058f610008129","authors":["Wendy L Lipworth","Ken Ho","Ian H Kerridge","Richard O Day"],"doi":"10.5694\/mja11.11572","endpage":"205","first_seen_on":"2016-09-05T14:09:04+00:00","issns":["0025729X","13265377"],"issue":"4","journal":"Medical Journal of Australia","last_mentioned_on":1415657471,"links":["http:\/\/dx.doi.org\/10.5694\/mja11.11572"],"pmid":"22900859","pubdate":"2012-08-20T00:00:00+00:00","publisher_subjects":[{"name":"Public Health And Health Services","scheme":"era"},{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"204","title":"Drug policy at the margins: the case of growth hormone replacement for adults with severe growth hormone deficiency","type":"article","volume":"197","mendeley_url":"http:\/\/www.mendeley.com\/research\/drug-policy-margins-case-growth-hormone-replacement-adults-severe-growth-hormone-deficiency-2"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":6953394,"mean":6.2315395168925,"rank":1624720,"this_scored_higher_than_pct":65,"this_scored_higher_than":4536525,"rank_type":"exact","sample_size":6953394,"percentile":65},"similar_age_3m":{"total_number_of_other_articles":234980,"mean":11.778669753467,"rank":74868,"this_scored_higher_than_pct":66,"this_scored_higher_than":157357,"rank_type":"exact","sample_size":234980,"percentile":66},"this_journal":{"total_number_of_other_articles":1325,"mean":8.9472658610272,"rank":495,"this_scored_higher_than_pct":34,"this_scored_higher_than":457,"rank_type":"exact","sample_size":1325,"percentile":34},"similar_age_this_journal_3m":{"total_number_of_other_articles":31,"mean":22.281666666667,"rank":19,"this_scored_higher_than_pct":35,"this_scored_higher_than":11,"rank_type":"exact","sample_size":31,"percentile":35}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Postgraduate":1,"Student  > Master":1,"Student  > Bachelor":2,"Lecturer":1,"Researcher":1},"by_discipline":{"Medicine and Dentistry":5,"Agricultural and Biological Sciences":1}}}},"posts":{"policy":[{"title":"Funding rare disease therapies in Australia: ensuring equitable access to health care for all Australians","url":"http:\/\/mckellinstitute.org.au\/wp-content\/uploads\/pdf\/McKell_RareDiseases_A4-New-web.pdf","license":"public","citation_ids":[3919966,15421917,11762900,3082470,173420,864425,594371,11765423],"posted_on":"2014-11-10T22:11:11+00:00","source":{"name":"Australian Policy Online","description":"Australia Policy Online (APO) is a research database and alert service providing free access to full-text research reports and papers, statistics and other resources essential for public policy development and implementation in Australia and New Zealand.","geo":{"country":"AU"}},"page_url":"http:\/\/apo.org.au\/node\/42705","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-aedb493a8ad2800d836af04e22accceb08e51d1e87282c540cbba8ca3f7b1151.jpg"}}]}}